Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors

Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors

In today’s global plan to completely eradicate hepatitis C virus (HCV), the essential list of medications used for HCV treatment are direct-acting antivirals (DAAs), as interferon-sparing regimens have become the standard-of-care (SOC) treatment. HCV nonstructural protein 5A (NS5A) inhibitors are a...

Full description

Bibliographic Details
Main Authors: Jehad Hamdy, Nouran Emadeldin, Mostafa M. Hamed, Efseveia Frakolaki, Sotirios Katsamakas, Niki Vassilaki, Grigoris Zoidis, Anna K. H. Hirsch, Mohammad Abdel-Halim, Ashraf H. Abadi
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Pharmaceuticals
Subjects:
direct-acting antivirals
NS5A inhibitors
HCV antivirals
pan-genotypic activity
Gt1b molecular docking
diphenyldiyne core
Online Access:https://www.mdpi.com/1424-8247/15/5/632

Internet

https://www.mdpi.com/1424-8247/15/5/632

Similar Items